Regulatory B cells in anti-tumor immunity

Yu Zhang, Nicolas Gallastegui, Joseph D Rosenblatt

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic sub-populations in inhibition of the anti-tumor immune response. The role of B cells in modulating the immune response to solid tumors as well as lymphoid malignancies is less well understood. Murine models of autoimmune disease have defined B regulatory cell (Breg) subsets with immune suppressive activity, including B cell subsets that express IL-10, and transforming growth factor-β, which can facilitate T regulatory cell recruitment and expansion. Multiple murine tumor models point to the existence of similar immune suppressive B cell sub-populations that can migrate into tumor deposits and acquire an immune suppressive phenotype, which then leads to attenuation of the local anti-tumor immune response. Other murine models of viral or chemically induced skin carcinogenesis have identified a pivotal role for B cells in promoting inflammation and carcinogenesis. While many human solid tumors demonstrate significant B cell infiltration and/or tertiary lymphoid structure formation, the functional properties of tumor-infiltrating B cells and their effects on immunity are poorly understood. Recent successes in early Phase I/II trials using anti-checkpoint inhibitor antibodies such as nivolumab or pidilizumab directed against PD-1 in the setting of Hodgkin's and non-Hodgkin's lymphomas validate the therapeutic utility of reversing B cell-mediated immune suppression. Further studies to define Breg subsets, and mechanisms of suppression, may provide new avenues for modulation of the immune response and meaningful therapeutic intervention in both lymphoid and solid tumors.

Original languageEnglish (US)
Pages (from-to)521-530
Number of pages10
JournalInternational Immunology
Volume27
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Regulatory B-Lymphocytes
Immunity
B-Lymphocytes
B-Lymphocyte Subsets
Neoplasms
Carcinogenesis
Transforming Growth Factors
Regulatory T-Lymphocytes
Immunosuppressive Agents
Hodgkin Disease
Interleukin-10
Non-Hodgkin's Lymphoma
Population
Autoimmune Diseases

Keywords

  • Anti-tumor immunity
  • B regulatory cells
  • IL-10
  • TGF-β

ASJC Scopus subject areas

  • Immunology

Cite this

Regulatory B cells in anti-tumor immunity. / Zhang, Yu; Gallastegui, Nicolas; Rosenblatt, Joseph D.

In: International Immunology, Vol. 27, No. 10, 01.10.2015, p. 521-530.

Research output: Contribution to journalArticle

Zhang, Yu ; Gallastegui, Nicolas ; Rosenblatt, Joseph D. / Regulatory B cells in anti-tumor immunity. In: International Immunology. 2015 ; Vol. 27, No. 10. pp. 521-530.
@article{5fc3cb92aad543198b6e738ab155c8af,
title = "Regulatory B cells in anti-tumor immunity",
abstract = "Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic sub-populations in inhibition of the anti-tumor immune response. The role of B cells in modulating the immune response to solid tumors as well as lymphoid malignancies is less well understood. Murine models of autoimmune disease have defined B regulatory cell (Breg) subsets with immune suppressive activity, including B cell subsets that express IL-10, and transforming growth factor-β, which can facilitate T regulatory cell recruitment and expansion. Multiple murine tumor models point to the existence of similar immune suppressive B cell sub-populations that can migrate into tumor deposits and acquire an immune suppressive phenotype, which then leads to attenuation of the local anti-tumor immune response. Other murine models of viral or chemically induced skin carcinogenesis have identified a pivotal role for B cells in promoting inflammation and carcinogenesis. While many human solid tumors demonstrate significant B cell infiltration and/or tertiary lymphoid structure formation, the functional properties of tumor-infiltrating B cells and their effects on immunity are poorly understood. Recent successes in early Phase I/II trials using anti-checkpoint inhibitor antibodies such as nivolumab or pidilizumab directed against PD-1 in the setting of Hodgkin's and non-Hodgkin's lymphomas validate the therapeutic utility of reversing B cell-mediated immune suppression. Further studies to define Breg subsets, and mechanisms of suppression, may provide new avenues for modulation of the immune response and meaningful therapeutic intervention in both lymphoid and solid tumors.",
keywords = "Anti-tumor immunity, B regulatory cells, IL-10, TGF-β",
author = "Yu Zhang and Nicolas Gallastegui and Rosenblatt, {Joseph D}",
year = "2015",
month = "10",
day = "1",
doi = "10.1093/intimm/dxv034",
language = "English (US)",
volume = "27",
pages = "521--530",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Regulatory B cells in anti-tumor immunity

AU - Zhang, Yu

AU - Gallastegui, Nicolas

AU - Rosenblatt, Joseph D

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic sub-populations in inhibition of the anti-tumor immune response. The role of B cells in modulating the immune response to solid tumors as well as lymphoid malignancies is less well understood. Murine models of autoimmune disease have defined B regulatory cell (Breg) subsets with immune suppressive activity, including B cell subsets that express IL-10, and transforming growth factor-β, which can facilitate T regulatory cell recruitment and expansion. Multiple murine tumor models point to the existence of similar immune suppressive B cell sub-populations that can migrate into tumor deposits and acquire an immune suppressive phenotype, which then leads to attenuation of the local anti-tumor immune response. Other murine models of viral or chemically induced skin carcinogenesis have identified a pivotal role for B cells in promoting inflammation and carcinogenesis. While many human solid tumors demonstrate significant B cell infiltration and/or tertiary lymphoid structure formation, the functional properties of tumor-infiltrating B cells and their effects on immunity are poorly understood. Recent successes in early Phase I/II trials using anti-checkpoint inhibitor antibodies such as nivolumab or pidilizumab directed against PD-1 in the setting of Hodgkin's and non-Hodgkin's lymphomas validate the therapeutic utility of reversing B cell-mediated immune suppression. Further studies to define Breg subsets, and mechanisms of suppression, may provide new avenues for modulation of the immune response and meaningful therapeutic intervention in both lymphoid and solid tumors.

AB - Advances in understanding of the immune microenvironment have highlighted the role of immunosuppressive T cell, myeloid, dendritic and monocytic sub-populations in inhibition of the anti-tumor immune response. The role of B cells in modulating the immune response to solid tumors as well as lymphoid malignancies is less well understood. Murine models of autoimmune disease have defined B regulatory cell (Breg) subsets with immune suppressive activity, including B cell subsets that express IL-10, and transforming growth factor-β, which can facilitate T regulatory cell recruitment and expansion. Multiple murine tumor models point to the existence of similar immune suppressive B cell sub-populations that can migrate into tumor deposits and acquire an immune suppressive phenotype, which then leads to attenuation of the local anti-tumor immune response. Other murine models of viral or chemically induced skin carcinogenesis have identified a pivotal role for B cells in promoting inflammation and carcinogenesis. While many human solid tumors demonstrate significant B cell infiltration and/or tertiary lymphoid structure formation, the functional properties of tumor-infiltrating B cells and their effects on immunity are poorly understood. Recent successes in early Phase I/II trials using anti-checkpoint inhibitor antibodies such as nivolumab or pidilizumab directed against PD-1 in the setting of Hodgkin's and non-Hodgkin's lymphomas validate the therapeutic utility of reversing B cell-mediated immune suppression. Further studies to define Breg subsets, and mechanisms of suppression, may provide new avenues for modulation of the immune response and meaningful therapeutic intervention in both lymphoid and solid tumors.

KW - Anti-tumor immunity

KW - B regulatory cells

KW - IL-10

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=84946713832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946713832&partnerID=8YFLogxK

U2 - 10.1093/intimm/dxv034

DO - 10.1093/intimm/dxv034

M3 - Article

VL - 27

SP - 521

EP - 530

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 10

ER -